Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation (CERS) maintains global leadership in blood safety through its INTERCEPT Blood System, a pathogen inactivation platform protecting transfusion medicine worldwide. This dedicated news hub provides investors and healthcare professionals with essential updates on regulatory milestones, clinical advancements, and operational developments.
Access timely reports on FDA clearances, European CE marks, and partnerships with blood centers across 40+ countries. Track progress in platelet and plasma treatment adoption, red blood cell system trials, and international expansion efforts. Our curated news collection ensures you never miss critical updates about this biomedical innovator.
Key coverage areas include quarterly financial results analysis, peer-reviewed study publications, manufacturing capacity expansions, and strategic collaborations with global health organizations. All content is verified through primary sources including company filings and official statements.
Bookmark this page for streamlined access to CERS developments impacting transfusion safety standards. Combine real-time alerts with historical context to understand Cerus' role in combating emerging bloodborne pathogens through cutting-edge nucleic acid targeting technology.
Cerus (CERS) has scheduled the release of its first quarter 2025 financial results for Thursday, May 1, 2025, after market close. The company will host a conference call and webcast at 4:30 P.M. ET on the same day to discuss financial performance and provide business updates.
Management will present detailed financial results and offer a general business overview and outlook during the call. A replay of the event will be accessible on Cerus' website until May 22, 2025.
Cerus (CERS) has received CE mark approval for its next-generation LED-based illumination device (INT200) for the INTERCEPT Blood System for platelets and plasma under the EU Medical Device Regulation (MDR). This approval enables Cerus to market the INT200 throughout the European Union and regions recognizing CE mark certification.
The INT200 represents a significant upgrade featuring enhanced physical design and new software interface while maintaining compatibility with existing processing sets. This approval completes the authorization of the INTERCEPT Blood System for both platelets and plasma within the EU MDR framework, following the 2023 CE mark approvals of INTERCEPT processing sets.
The CE mark represents the first regulatory approval for Cerus' next-generation illuminator, with additional regulatory submissions planned over coming years. The INT200 will serve as the foundation for geographic expansion and future growth of the INTERCEPT business.
Cerus (CERS) reported strong financial results for full-year and Q4 2024. Full-year product revenue reached $180.3 million, up 15% year-over-year, while Q4 product revenue was $50.8 million, a 9% increase. The company achieved significant financial improvements, including a 40% reduction in GAAP net loss to $20.9 million and positive non-GAAP adjusted EBITDA of $5.7 million for 2024.
Notable achievements include four consecutive quarters of positive operating cash flows, totaling $11.4 million for the year, a $55 million improvement from 2023. The INTERCEPT Fibrinogen Complex (IFC) product showed strong growth, with full-year revenue of $9.2 million, up 42% from the previous year.
The company reiterated its 2025 product revenue guidance of $194-200 million, including $12-15 million for IFC, projecting 8-11% growth from 2024.
Cerus (Nasdaq: CERS) has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's management team is scheduled to present at a fireside chat on Wednesday, March 5, at 11:10 a.m. EST. The presentation will be accessible through a live webcast, with a replay available for 90 days following the event.
Cerus (Nasdaq: CERS) has scheduled the release of its fourth quarter and full-year 2024 financial results for Thursday, February 20, 2025, after market close. The company will host a conference call and webcast at 4:30 P.M. ET on the same day, featuring management discussions on financial results, business overview, and outlook.
Interested participants can access the webcast and presentation slides through Cerus' Investor Relations webpage at http://ir.cerus.com. While early joining is encouraged (10 minutes prior), it's not mandatory. A replay of the event will be available on the company's website approximately three hours after the call until March 6, 2025.
Cerus (CERS) reported preliminary full-year 2024 product revenue of $180.3 million, exceeding their guidance of $177-$179 million and marking a 15% increase over 2023. The growth was driven by strong performance in their INTERCEPT platelet franchise and IFC business, which grew 42% to reach $9.2 million in revenue.
For 2025, Cerus projects product revenue between $194-$200 million, representing 8-11% year-over-year growth. IFC revenue is expected to range from $12-$15 million. The company anticipates Q1 2025 product revenue growth of 10-15% compared to Q1 2024. Future initiatives include the planned LED Illuminator launch in Europe and geographic expansion efforts.
Cerus (Nasdaq: CERS) has announced its participation in two upcoming investor conferences. Management will present at the Stifel 2024 Healthcare Conference on Monday, November 18th at 4:10 PM ET, and attend the Craig-Hallum Alpha Select Conference on Tuesday, November 19th. A live webcast of the Stifel conference presentation will be available online, with a replay accessible on the company's website following the event.
Cerus (CERS) reported strong Q3 2024 financial results with product revenue increasing 16% to $46.0 million. The company raised its full-year 2024 product revenue guidance to $177-179 million. Q3 highlights include a new $248 million BARDA contract for INTERCEPT RBCs, expanded U.S. manufacturing capacity for INTERCEPT Fibrinogen Complex, and improved financial metrics with GAAP net loss narrowing to $2.9 million. Product gross margin improved to 56.9%, and the company generated positive operating cash flows of $4.1 million. However, CE Mark review for INTERCEPT RBCs concluded without approval.
Cerus (Nasdaq: CERS) has announced that it will release its third quarter 2024 financial results on Wednesday, October 30, 2024, after the stock market closes. The company will host a conference call and webcast at 4:30 P.M. ET on the same day to discuss the financial results and provide a general business overview and outlook.
Interested parties can listen to the live webcast and view presentation slides on the Investor Relations page of Cerus' website at http://ir.cerus.com. Participants are encouraged to register for the call and join 10 minutes before the event starts. A replay of the call will be available on Cerus' website approximately three hours after the call and will remain accessible until November 20, 2024.
Cerus (CERS) announced a selection of abstracts to be presented at the 2024 AABB Annual Meeting in Houston, Texas from October 19-22. The presentations highlight real-world utilization of INTERCEPT-treated blood products, including INTERCEPT Fibrinogen Complex, and recent findings from the Phase 3 ReCePI Clinical Trial.
Key presentations include:
- Outcomes of the ReCePI Phase III Clinical Trial evaluating pathogen-reduced red cells in cardiac surgery
- Efficiency of INTERCEPT Fibrinogen Complex vs traditional cryoprecipitate
- Phase IV TOPCLOT trial comparing pathogen-reduced cryoprecipitate to cryoprecipitated AHF in cardiac surgery
- HLA alloimmunization and treatment-emergent antibodies in the ReCePI study
Poster presentations will cover topics such as pathogen reduction efficacy, next-generation illuminator development, and implementation of pathogen-reduced blood products. Cerus will also host an industry workshop on current experiences and future developments with the INTERCEPT Blood System.
